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MATERIALS and METHODS
As part of the Vestibular Schwannoma Project conducted by the EAONO, a comprehensive literature search was performed to ex-
amine the protocols used for the follow-up of vestibular schwannoma (VS) following the wait and scan management. 
An English literature review was conducted using the PubMed database and reached as far back as the year 2000 and was updated 
until August 2015. 
A PubMed search using the keywords “vestibular schwannoma,” “acoustic neuroma,” and “conservative management” alone and in 
combination was performed.
This query identified 163 studies between 2000 and 2015. 
Search syntax
(“neuroma, acoustic” [MeSH terms] OR (“neuroma” [all fields] AND “acoustic” [all fields]) OR “acoustic neuroma” [all fields] OR (“vestib-
ular” [all fields] AND “schwannoma” [all fields]) OR “vestibular schwannoma” [all fields]) AND conservative [all fields]
Inclusion and exclusion criteria
Article titles and abstracts were screened for the following criteria:
a) clinical articles reporting original data, thus excluding reviews and case reports
b) presented data only on adults
c) series using conservative management for solitary VS
d) series with > 30 patients were included
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The wait and scan policy is being increasingly used as the first measure after the diagnosis of a vestibular schwannoma (VS) using magnetic resonance 
imaging (MRI). As part of the European Academy of Otology & Neuro-Otology (EAONO) position statement on VS, the frequency of imaging has been 
studied in the literature. Among 163 studies, 29 fulfilled the inclusion criteria and were scored using the Grading of Recommendations, Assessment, De-
velopment, and Evaluation system. Because tumor growth rate during the first 5 years of follow-up is predictive of further growth during the upcoming 
years, a protocol for wait and scan is useful for centers dealing with this condition. The EAONO proposal is that after the initial diagnosis by MRI, a first new 
MRI would take place after 6 months, annually for 5 years, and then every other year for 4 years, followed by a lifelong MRI follow-up every 5 years. The 
first early MRI is to screen for fast-growing tumors, and the lifelong follow-up with tapered intervals is to detect late repeated growth.  
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e) quantitative assessment of VS surveillance as one of the primary 
study end-points
f ) mean follow-up of at least 3 years
g) studies in which the reported data included patients with neu-
rofibromatosis type 2, and if these data could not be separately 
identified from the reported data for patients with VS, were ex-
cluded
h) the frequency of magnetic resonance imaging (MRI) follow-up 
must be mentioned in the Materials and methods section with 
preferably the presentation of a protocol of conservative man-
agement
The initial search yielded 163 articles, but 134 articles that did not 
meet one or more of these inclusion criteria were excluded. Only 29 
articles of which the methodology was reviewed and scored using 
the Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE) system remained. 
RESULTS
The question: 
What is the required frequency of MRI scanning in the wait and scan 
management?
INTRODUCTION
A conservative treatment strategy is often proposed as a primary treat-
ment option in the management of VS. This can be justified because the 
growth rate of VSs is known to be extremely variable, with most tumors 
remaining stable or showing only minimal growth for several years. To-
day, this option is widely adopted in small- or medium-sized tumors or 
tumors without contact with the brainstem. Because it is impossible to 
predict the expected behavior of an individual VS based on the infor-
mation available at diagnosis (age, sex, tumor laterality, and tumor size 
at presentation), tumor growth rate must be established by means of 
radiological surveillance, and the imaging interval cannot be guided by 
LITERATURE REVIEW 
     Follow-up % of tumors % change in GRADE GRADE 
  Study  Frequency time months presenting strategy, surgery, Quality of Strength of 
Author Year design Number of MRI  (range or SD) no growth or radiotherapy? evidence recommendation
Jethanamest et al. [1] 2015 Retrospective study 94 Annual 34.8 (SD32.8) 37.8%  22.3% Low Weak
González-Orús  2014 Retrospective study 73 First at 6 months, 35.75 (12-240) 87.7%  8.2% Low Weak 
Álvarez-Morujo et al. [2]    then annually  
    If growth every  
    6 months
Fayad et al. [3] 2014 Retrospective study 114 “Serial” 57.6 (SD=43) 62%  31% Low Weak
Nikopoulos et al. [4] 2013 Meta-analysis NA  Variable  NA From 6% to 73% NM Moderate Weak
Ferri et al. [5] 2013 Retrospective study 161 6 months,  73.2 (8-162) 64.2% 62% (37.9% surgery, Low Weak 
    annually   24.1% radiotherapy)
Stangerup and 2012 Review of own 2500 Annually in the NM NM NM Moderate Weak 
Caye-Thomasen [6]  retrospective studies  study proposal  
    Yearly for 5 years  
    Followed up by  
    MRI every other  
    year for 4 years  
    Followed up by  
    MRI 5 years later  
    then stop
Moffat et al. [7] 2012 Prospective study 381 Every 6 months,  50.4 (6-204) 67%  NM Low Weak 
    annually for the  
    next 3 years, every  
    2 years for 6 years,  
    then every 3 years
Breivik et al. [8] 2012 Prospective study 186 6 months, 1, 2  46 (9-115) 60% 40% (9% surgery, Moderate Weak 
    and 5 years    31% radiotherapy)
Kaltoft et al. [9] 2011 Retrospective study 959 6 mo, annually 61 73%  17% Low Weak
Hughes et al. [10] 2011 Retrospective study 59 Annually 68 (11-156) 81% 19%  Low Weak
van de Langenberg  2011 Retrospective study 36 Annually 20 mo (12-67) 68%  NM Low Weak 
et al. [11]
Agrawal et al. [12] 2010 Retrospective study 180 Annually 32 63%  35% (surgery or  Moderate Weak 
       radiotherapy)
Suryanarayanan  2010 Retrospective study 286 Annually 43,2 (12-168) 68% % (21% surgery, Low Weak 
et al. [13]        254% radiotherapy)
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the baseline data. Only tumor growth rate during the first years of fol-
low-up is predictive of further growth during the upcoming years. Pro-
tocols for wait and scan have been proposed in the literature and are 
based on data from the observation of the natural history of VSs in co-
horts of patients usually followed up annually over a prolonged period.  
EVIDENCE
The reviewed literature was studied to find an answer to how often 
should VS be screened for growth. This review comprised 2 me-
ta-analyses, 4 prospective cohort studies, and 23 retrospective case 
series. A total of 8711 patients were included in these studies. The 
mean number of patients who were included for the clinical series 
was 215 (50-2500). 
Most studies were initially designed to study the growth rate of VS 
and found a decreasing percentage of growing tumors along the ob-
servation time. 
The wait and scan policy had to be changed into an active manage-
ment in 23% of the cases (range: 7%-62%), and surgery was adopted 
in 14% and radiotherapy in 9% of the cases. 
Although the overall quality of the previous studies is low, all point in 
the same direction, suggesting a significant reduction of new growing 
tumors during longer observation times. Following the GRADE system, 
24 articles were considered to have a “low” level of evidence for being 
observational studies. Two meta-analyses and 3 good quality obser-
LITERATURE REVIEW (Continued)
     Follow-up % of tumors % change in GRADE GRADE 
  Study  Frequency time months presenting strategy, surgery, Quality of Strength of 
Author Year design Number of MRI  (range or SD) no growth or radiotherapy? evidence recommendation 
Bakkouri et al. [14]  2009 Retrospective study 325 At 1 year, then  NM (Range 76% 24% (18.4% surgery, Low Weak 
    every 2 years 1-9 years)   5% radiotherapy)
Martin et al. [15] 2009 Retrospective study 276 6months,  43 73% 8% surgery, Low Weak 
    1 year, 1 year,    11% radiotherapy 
    2 years, 5 years 
    lifelong      
Verma et al. [16] 2009 Retrospective study 72 6m,1y, annually  121 60%  40%  Low Weak 
    and subsequently  
    every 2-3 y
Ferri et al. [17] 2008 Cohort prospective  123 6mo, 6mo, 57.4 (6-182) 64% 13% surgery,  Low Weak 
  study  annually     7% radiotherapy, 
       2% lost to follow-up
Nedzelski et al. [18] 2008 Retrospective study 50 Every 6 months,  41.7 (7-152) 51% 22% surgery, Low Weak 
    few years, then    2% radiotherapy 
    annually       
Hajioff et al. [19] 2008 Retrospective study 72 6 months,  121 (89-271) 60% 35% 11% surgery, Low Weak 
    6 months, every    19% radiotherapy 
    1-2 years      
Martin et al. [20] 2008 Retrospective study 167 Annually for 62 65% 11% surgery, Low Weak 
    5 years, then    11% radiotherapy 
    every 5 years     
Stangerup et al. [21] 2006 Case series  552 Yearly for 5 years 42 (12-180) 76% Intrmeatal 13% surgery, Moderate Weak 
  prospective  Every other year   83% Extrameatal 1% radiotherapy 
    for 4 years MRI   70% 
    after 5 years Stop    
Battaglia et al. [22] 2006 Retrospective study 109 Annually 38 (12-156) 71%  8% Low Weak
Al Sanosi et al. [23] 2006 Retrospective study 205 Annually 40.8 (12-184) 66.3%  7% Low Weak
Yoshimoto [24] 2005 Meta-analysis 1340 NA 38 56% 18% 14 surgery,  Moderate Weak 
       4% radiotherapy
Bozorg Grayeli et al. [25] 2005 Retrospective study 111 Annually 33 (6-111) 53%  16%  Low Weak
Raut et al.  [26] 2004 Case series prospective 72 6 months, annually 80(52-242) 59.3%  32% Low Weak
Perry et al. [27] 2001 Retrospective study 41 Annually 42 (6-108) 79% surgery Low Weak
Rosenberg [28] 2000 Retrospective study 80 Annually 57,6 6-206 42% 7.5% Low Weak
Shin et al. [29] 2000 Retrospective study 87 Every 1-2 years 31 (4-120) 62% 12% 6% surgery,  Low Weak 
       6% radiotherapy
NA: not applicable; NM: not mentioned; Y: year; MO: month; GRADE: grading of recommendations, assessment, development, and evaluation
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vational studies were graded as “moderate” evidence. None of the 
studies achieved a grade with strength of recommendation better 
than weak.
CONCLUSION
The quality of evidence and strength of recommendation remains 
low despite the abundance of studies in this field. This may be ex-
plained by methodological issues in the clinical research of such a 
delicate problem as VS. 
1. Nevertheless, most studies arrive at similar conclusions:
2. In order to screen for rapidly-growing tumors, one may perform 
a first control 6 months after the initial diagnosis.
3. Annual controls were performed for research purposes and were 
pursued by most authors.
4. If tumor growth occurs, this will most likely happen within the 
first years after diagnosis.
5. After 5 years, further growth of a tumor that remained stable 
for years becomes unlikely but may still occur. A lifelong surveil-
lance is, therefore, advised but with tapered, longer intervals.
6. Too regular initial MRI controls may give a false sense of security 
to patients and discourage them to repeat MRI over a lifelong 
period. Reducing the number of follow-up scans should have a 
positive effect on follow-up reliability and health care expenses.
7. A protocol should be easy to use and easy to remember by the 
health care providers and by the patients.
Remarks
Most of the available evidence of VS growth and proposed protocols 
come from retrospective case series. The definition of growth varied 
from 1 mm to >2 mm per year. The follow-up period was quite het-
erogeneous and usually too short in comparison with the life expec-
tancy of most patients with VS. 
Position of EAONO
• Distinguishing individual patients whose tumors will grow and 
pose a threat to them from those whose tumors will likely re-
main stable or even regress is central to the current manage-
ment of patients with VS.
• Since most lesions do not grow, a wait and scan strategy seems 
justified in several patients.
• Evidence of tumor growth has become the defining criterion for 
intervention, especially for small- and medium-sized tumors.
• When to discharge a patient from a regime of interval scanning 
remains uncertain, some evidence indicates that most tumor 
growth occurs in the first 5 years after identification. However, 
this is not always the case because cases with late growth after 
prolonged tumor quiescence have been reported.
• Clinicians should seek to instigate national tumor registries in 
their countries and common data set to facilitate international 
cooperation. 
• For the present, the EAONO proposes a protocol mainly based 
on the Danish experience. Only one additional 6 months re-
peat MRI after the initial diagnosis could be added to find for 
fast-growing tumors and a five yearly repeat MRI in the long run.
• Initial diagnosis by MRI
• First MRI 6 months later
• Yearly MRI for 5 years
• Then, MRI every other year for 4 years
• Then, MRI every 5 years, lifelong
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Editor’s Note:
The EAONO Project on guidelines of Otology and Neurotology was initiated by 
Franco Trabalzini and the Working Groups began working in 2011. Since then a 
considerable work has been issued to produce the first Consensus Documents.
The working Group on Vestibular Schwannoma have esteemed members 
from dedicated centers all over Europe. I wish to express my thanks to the 
working group leaders Miguel Aristegui and Jacques Magnan for their great 
effort as well as to all the other active members of the group. 
Miguel Aristegui, Shakeel Saeed, Simon Lloyd, Per-Caye Thomasen and 
Jacques Magnan’s comments for this “Consensus Document” have been very 
much appreciated.
This study is very much respected by the Editorial of the Journal in this regard.
Prof. Dr. O. Nuri Ozgirgin
Editor in Chief  
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